Canada · Delayed Price · Currency is CAD Perimeter Medical Imaging AI Earnings Call Transcripts
Fiscal Year 2026
-
A newly FDA-approved AI imaging device for breast cancer surgery is entering commercialization, targeting a large U.S. and global market with a high-margin, recurring revenue model. Expansion plans include new cancer types, international growth, and a NASDAQ listing, supported by ongoing fundraising.
Fiscal Year 2025
-
Record Q4 2025 revenue and reduced losses reflect strong S-Series adoption and cost controls. FDA PMA approval for Claire OCT sets the stage for commercial launch and broader market penetration in 2026, with new recurring revenue streams anticipated.
-
The meeting confirmed quorum, reviewed financials, elected directors, and approved KPMG LLP as auditor. Amendments to the Omnibus Equity Incentive Plan were passed, increasing issuable shares to support future incentives. All motions were approved by shareholder vote.
-
Q3 2025 saw 157% revenue growth and a 34% reduction in operating expenses, with strong S Series adoption and a pivotal B Series trial success. FDA approval for the B Series is expected in early 2026, positioning for accelerated growth and market expansion.
-
A novel imaging device using OCT and AI dramatically reduces cancer surgery re-operation rates, improving patient outcomes and lowering costs. With strong clinical results, high-margin consumables, and a unique data library, the company is poised for rapid U.S. expansion and multi-billion dollar market growth.
-
High re-operation rates in cancer surgery drive demand for real-time, high-resolution imaging solutions. The FDA-cleared S-Series device and upcoming AI-enabled B-Series have shown strong clinical and commercial traction, reducing re-operations and driving high-margin recurring revenue.
-
Q2 2025 saw 105% revenue growth and strong S-Series OCT adoption, with operating expenses down 22%. B-Series OCT pivotal trial met its endpoint and is under FDA review, with approval expected late 2025 or early 2026. Cash conservation and new leadership support continued growth.
-
High rates of repeat cancer surgeries drive significant costs and lower survival rates. A new wide-field OCT device, soon to be AI-enabled, enables real-time margin assessment, reducing reoperations and improving outcomes. FDA approval for the AI device is expected by year-end.
-
Q1 2025 revenue grew 460% year-over-year, driven by consumables, warranty programs, and the first capital sale. The B-Series pivotal trial met its endpoints, supporting an FDA PMA submission, while commercial momentum and hospital adoption continue to accelerate.
-
Achieving clean surgical margins remains a major challenge, driving high costs and poor outcomes. The company’s wide-field OCT technology, now enhanced with AI, has demonstrated significant reductions in re-operation rates and is poised for broader adoption pending FDA approval.
-
Wide-field OCT and AI technology significantly reduce re-operation rates in cancer surgery, with strong clinical trial results and a high-margin consumable business model. Market expansion targets other solid tumors, and the company is well-positioned with robust IP, manufacturing, and financial planning.
Fiscal Year 2024
-
Revenue grew 303% year-over-year in Q4 2024, driven by increased S-Series installations and utilization. The pivotal trial for the AI-enabled B-Series met its primary endpoint, leading to a PMA submission to the FDA and setting the stage for a major commercial launch.
-
The meeting confirmed quorum, reviewed financial statements for 2022 and 2023, and elected five directors. KPMG LLP was reappointed as auditor, and all motions were passed by electronic vote.
-
The pivotal trial for the B-Series OCT with ImgAssist AI 2.0 met its primary endpoint, showing a significant reduction in residual cancer during breast-conserving surgery and demonstrating superiority over standard care. A PMA submission is planned for early 2025, with FDA approval expected to enable rapid commercial adoption.
-
Q3 2024 saw stable operating expenses, a higher net loss due to non-cash items, and $208,000 in revenue. Enrollment in the pivotal B-Series AI trial was completed, with top-line results and an FDA submission expected soon, positioning the company for a major commercial inflection.
-
Q2 2024 saw revenue grow 83% year-over-year and net loss improve 35%, with accelerated S-Series OCT adoption and 1,000 patient scans achieved. The pivotal B-Series OCT trial is ahead of schedule, with top-line data expected in Q4 and FDA submission in early 2025.
-
OCT-based technology with AI integration is reducing reoperation rates and improving outcomes in oncological surgery. Strong clinical evidence, robust IP, and a high-margin recurring revenue model support expansion, with FDA approval for the next-gen B-Series targeted for late 2025.